SCHEMBL5533223

SCHEMBL5533223

O=C(O)c1ccc(Cl)c(N2C(=O)c3cccc4c(-n5cccc5)ccc(c34)C2=O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
ALDH1A1 P00352 5/20 0.60
MEN1 O00255 4/20 0.60
KDM4E B2RXH2 4/20 0.60
POLB P06746 5/20 0.52
L3MBTL1 Q9Y468 5/20 0.52
CASP6 P55212 3/20 0.52
TLR9 Q9NR96 2/20 0.52
TDP1 Q9NUW8 4/20 0.48
RECQL P46063 2/20 0.48
RXFP1 Q9HBX9 2/20 0.48
APEX1 P27695 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
TSHR P16473 2/20 0.47
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
ERCC1 P07992 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5156075 0.89 ALDH1A1 (0.73) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5150071 0.86 POLB (0.66) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5159082 0.85 KMT2A (0.61) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5166838 0.85 KMT2A (0.61) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL14502327 0.83 TDP1 (0.56) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5150543 0.82 KMT2A (0.70) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5533701 0.82 ALDH1A1 (0.60) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL14510361 0.81 MEN1 (0.77) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL5133255 0.78 ALDH1A1 (0.51) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL8190895 0.77 TSHR (0.55) KMT2AALDH1A1MEN1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KMT2A 4267/4885ALDH1A1 2086/4885MEN1 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.